Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia

Archives of Ophthalmology

Volumn 125, Issue 7, 2007, Pages 985-986

  Melicher Larson, Jill S ^a   Bergstrom, Lance K ^b   Cameron, J Douglas ^b   Erickson, Lori A ^b   Grimm, Terrence E ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; IMATINIB; PARAFFIN; PEROXIDASE; PROTEIN S 100;

AGED; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DISEASE COURSE; DISEASE SEVERITY; EYE EXAMINATION; EYELID; EYELID RECONSTRUCTION; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; LOWER EYELID; MALE; MICROSCOPY; PERIORBITAL EDEMA; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECURRENT DISEASE; SODIUM RESTRICTION; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; VISUAL ACUITY; VISUAL FIELD DEFECT;

AGED; EDEMA; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; ORBITAL DISEASES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 34447514471     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.7.985     Document Type: Article

References (5)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
2. Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2003.
3. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003;19(4):371-375.
4. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002;95(4):881-887.
5. Maalouf T, Angioi K, Champigneulle J, Guerci A, George JL. Palpebral edema secondary to treatment by a specific inhibitor of tyrosine kinase, Glivec: a case report [in French]. J Fr Ophtalmol. 2004;27(1):107-109.